What happens after the Semaglutide appointment?
The first prescription is one point on a longer timeline. Follow-up belongs in the first conversation.
What the weight trial found
In the STEP 1 trial, adults with obesity, or overweight plus a weight-related condition, without diabetes lost an average of 14.9% of their starting weight with semaglutide over 68 weeks. The placebo group lost 2.4%. Both groups received lifestyle support, and Novo Nordisk funded the trial.
Those numbers describe the study groups. They don't predict your result, and they don't describe medicine taken without the surrounding support. It's worth keeping the care setting in the picture.
STEP 1 tested a manufactured study medicine. It did not establish the safety or effectiveness of a compounded preparation.
What happened when treatment ended?
The STEP 1 extension followed a smaller group after both semaglutide and the lifestyle support ended. Over the following year, those previously taking semaglutide regained, on average, about two-thirds of the weight they had lost. Many measures of heart and metabolic health also moved back toward their starting levels.
That makes continuity worth discussing early. It doesn't show what every person will regain, or separate the effects of stopping medicine from stopping the support. Both ended in this study.
In another trial, people who switched to placebo after an initial semaglutide treatment period regained weight, while those continuing semaglutide lost more. It adds to the reason for asking about the longer plan.
Who was still in the study?
That second comparison involved people who reached the end of the initial treatment period. It doesn't describe everyone who first considered or started semaglutide. A continuation result and a starting-treatment result answer different questions.
Neither study supplies a personal stopping plan. The useful conversation is about why treatment might continue, how it will be reviewed and how a change would be handled. It doesn't need to wait until something goes wrong.
Follow-up includes how life is going
The Wegovy (semaglutide) label warns about digestive symptoms, including severe reactions and kidney injury linked to fluid loss. A favorable weight result doesn't erase those concerns. How treatment feels in daily life belongs beside the numbers.
Other changes matter too: a new medicine, pregnancy plans or a procedure under anesthesia can affect the review. The effects notes explain these label cautions. Weight is one part of the conversation.
A plan you can describe in plain words
Who reviews progress, and what can you raise between appointments? What happens if treatment is interrupted or becomes hard to tolerate? Who explains a revised plan?
The medical boards' model policy calls for needed tests or in-person assessment to be arranged. It's guidance for boards, rather than a single national law. Follow-up over a screen can include a referral elsewhere.
After the appointment, these are the questions that still need answers. Our preparation page helps bring them into the first visit, while the comparison notes keep study headlines in proportion.